Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in HER2-positive Hormone-refractory Prostate Cancer
NCT01320280Phase 2Terminated
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- May 2011
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib in prostate cancer (PCa), sponsored by University Medical Center Hamburg-Eppendorf. Started May 2011; status: terminated.
02
Drugs
afatinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01320280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01320280.